HIV treatment and care in resource-constrained environments: Challenges for the next decade

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Eholié, Serge Paul ^a,b,c   Aoussi, François Eba ^a,b   Ouattara, Ismael Songda ^a,b   Bissagnéné, Emmanuel ^a,b   Anglaret, Xavier ^c,d,e  

^a UNIVERSITÉ NANGUI ABROGOUA   (Côte d’Ivoire)

^b Teaching Hospital of Treichville   (Côte d’Ivoire)

^c Programme PAC CI   (Côte d’Ivoire)

^d INSERM   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Antiretroviral therapy; HIV; Resources constrained environments

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RIFAMPICIN; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ANEMIA; ANTIVIRAL THERAPY; AUTOMATION; BLOOD TOXICITY; BODY MASS; BUDGET; CASE FINDING; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CHRONIC KIDNEY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FETOTOXICITY; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; JUSTICE; LIVER TOXICITY; LOWEST INCOME GROUP; MORBIDITY; MORTALITY; NATURAL DISASTER; NEPHROTOXICITY; NOTE; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SCALE UP; SEX DIFFERENCE; SKIN TOXICITY; TUBERCULOSIS; VIRUS LOAD; DEVELOPING COUNTRY; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; METHODOLOGY; ORGANIZATION AND MANAGEMENT; REVIEW; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DELIVERY OF HEALTH CARE; DEVELOPING COUNTRIES; GUIDELINES AS TOPIC; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; TUBERCULOSIS; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 84872867484     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17334     Document Type: Note

References (97)

1. Katzenstein D, Laga M, Moatti JP. The evaluation of the HIV/AIDS drug access initiatives in Cote d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. AIDS. 2003;17(Suppl 3):S1-4.
2. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18- month follow-up study. AIDS. 2002;16:1363-70.
3. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-42.
4. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34-40.
5. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006;20:1163-9.
6. WHO, UNAIDS, UNICEF. Global HIV/AIDS Response. Epidemic update and Healthy Sector Progress Towards Universal Access: Progress report 2011. accessed 2011 Nov 30. Available from: http://www.who.int/hiv/pub/progress-report2011/en/ index.html.
7. UNAIDS. UNAIDS Report on the global AIDS epidemic. Geneva: UNAIDS; 2010. accessed 2011 Oct 15. Available from: http://www.unaids.org/globalreport/global- report.htm.
8. UNAIDS. Decline in AIDS funding risks jeopardizing recent gains made by countries. accessed 2011 Nov 27. Available from: http://www.unaids.org/en/ resources/presscentre/pressreleaseandstatementarchive/2011/november/ 20111127aidsfunding/
9. Hecht R, Stover J, Bollinger L, Muhib F, Case K, de Ferranti D. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet. 2010;376:1254-60.
10. Orsi F, Carrieri MP, Coriat B, Delaporte E, Moatti JP, Spire B, et al. Call for action to secure universal access to ART in developing countries. Lancet. 2010;375:1693-4.
11. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
12. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One. 2012;7:e30216.
13. Ventelou B, Arrighi I, Greener R, Lamontagne E, Carrieri P, Moatti JP. The macroeconomic consequences of renouncing to universal access to antiretroviral treatment for HIV in Africa: a Micro-Simulation Model. PLoS One. 2012;7:e34101.
14. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-908.
15. Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewiecki A, Cahn P, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr. 2009;51:615-23.
16. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-9.
17. MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg. 2009;103:588-93.
18. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS. 2005;19:2050-2.
19. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4- guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367:1981-9.
20. DART trial team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/ microl. AIDS. 2008;22:237-47.
21. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257-65.
22. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19:2109-16.
23. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21:2483-91.
24. Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, Chimzizi R, et al. The HIV-associated tuberculosis epidemic - when will we act? Lancet. 2010;375:1906-19.
25. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet. 1999;353:1463-8.
26. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet. 1999;353:1469-75.
27. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris BL, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 counts in HIV-infected adults before starting antiretroviral therapy in Côte d'Ivoire. Clin Infect Dis. 2012;54:714-23.
28. WHO. Antiretroviral therapy for HIV infection in adolescents and adults: recommendations for a public health approach. Geneva: World Health Organization; 2010. accessed 2012 June 1. Available from: http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf.
29. Stover J, Bollinger L, Avila C. Estimating the impact and cost of the WHO 2010 recommendations for antiretroviral therapy. AIDS Res Treat. 2011;2011:738271.
30. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med. 2009;151:157-66.
31. Nash D,Wu Y, Elul B, Hoos D, El Sadr W. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries. AIDS. 2011;25:1523-33.
32. Bassett IV, Giddy J, Nkera J,Wang B, Losina E, Lu Z, et al. Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr. 2007;46:181-6.
33. Ma W, Detels R, Feng Y,Wu Z, Shen L, Li Y, et al. Acceptance of and barriers to voluntary HIV counselling and testing among adults in Guizhou province, China. AIDS. 2007; 21(Suppl 8):S129-35.
34. Burke RC, Sepkowitz KA, Bernstein KT, Karpati AM, Myers JE, Tsoi BW, et al. Why don't physicians test for HIV? A review of the US literature. AIDS. 2007;21:1617-24.
35. Steen TW, Seipone K, Gomez Fde L, Anderson MG, Kejelepula M, Keapoletswe K, et al. Two and a half years of routine HIV testing in Botswana. J Acquir Immune Defic Syndr. 2007;44:484-8.
36. Konde-Lule J, Makumbi F, Pakker N, Muyinda A, Mubiru M, Cobelens FG. Effect of changing antiretroviral treatment eligibility criteria on patient load in Kampala, Uganda. AIDS Care. 2011;23:35-41.
37. Sanne I, Orrell C, Fox MP, Conradie F, Ive P, Zeinecker J, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010;376:33-40.
38. Lambdin BH, Micek MA, Koepsell TD, Hughes JP, Sherr K, Pfeiffer J, et al. Patient volume, human resource levels, and attrition from HIV treatment programs in central Mozambique. J Acquir Immune Defic Syndr. 2011;57:e33-9.
39. Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011;11:244.
40. MSF. Campaign for access to essential medicine, untangling the web of antiretroviral price reductions. 14th ed. 2011. accessed 2011 July 17. Available from: http://utw.msfaccess.org.
41. Renaud-Thery F, Avila-Figueroa C, Stover J, Thierry S, Vitoria M, Habiyambere V, et al. Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries. AIDS Res Treat. 2011;2011:749041.
42. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS. 2011;25:211-20.
43. Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010;50:416-25.
44. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12:753-60.
45. Messou E, Anglaret X, Duvignac J, Konan-N'dri E, Komena E, Gnokoro J, et al. Antiretroviral treatment changes in adults from Cote d'Ivoire: the roles of tuberculosis and pregnancy. AIDS. 2010;24:93-9.
46. Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005;41:376-85.
47. Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25:1603-9.
48. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, et al. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS. 2008;22:1821-7.
49. Reid A, Stohr W, Walker AS, Williams IG, Kityo C, Hughes P, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis. 2008;46:1271-81.
50. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, et al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr. 2010;54:63-70.
51. Bygrave H, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, et al. Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One. 2011;6:e17609.
52. Ekouevi DK, Coffie PA, Ouattara E, Moh R, Amani-Bosse C, Messou E, et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2011;56:183-7.
53. Ford N, Calmy A, Mofenson L. Safety of efavirenz in first-trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25:(18):2301-4.
54. Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr. 2006;42:29-35.
55. Ouattara E, Anglaret X,Wong A, Chu J, Smith HE, Danel C, et al. Projecting the clinical benefits and risks of using efavirenz-containing ART regimens in women of childbearing age in Sub-Saharan Africa. AIDS. 2012;26:625-34.
56. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis. 2007;44:128-34.
57. Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, et al. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Cote d'Ivoire. J Acquir Immune Defic Syndr. 2011;56:356-64.
58. Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS. 2011;25:1761-9.
59. Ferradini L, Ouk V, Segeral O, Nouhin J, Dulioust A, Hak C, et al. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc. 2011;14:14.
60. Messou E, Gabillard D, Moh R, Inwoley A, Sorho S, Eholie S, et al. Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults. Bull World Health Organ. 2008;86:435-42.
61. Badri M, Lawn SD,Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008;8:89.
62. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58:23-31.
63. Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010;54:258-68.
64. Rouet F, Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin Lab. 2007;53:135-48.
65. Bélec L, Bonn JP. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. Future Microbiol. 2011;6:1251-60.
66. Landier J, Akonde A, Pizzocolo C, Haidara I, Drabo M, Pizarro L, et al. Switch to second-line ART in West African routine care: incidence and reasons for switching. AIDS Care. 2011;23:75-8.
67. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010;304:303-12.
68. Seyler C, Adje-Toure C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D, et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS. 2007;21:1157-64.
69. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008;22:2097-106.
70. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11:510-8.
71. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58:23-31.
72. May Myat W, Maek ANW, Phonrat B, Kiertiburanakul S, Sungkanuparph S. Virologic and immunologic outcomes of the second-line regimens of antiretroviral therapy among HIV-infected patients in Thailand. J Int Assoc Physicians AIDS Care (Chic). 2011;10:57-63.
73. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Protease inhibitor resistance is uncommon in HIV-1 subtype c infected patients on failing secondline Lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat. 2011;2011:769627.
74. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.
75. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86:559-67.
76. Ekouevi DK, Balestre E, Ba-Gomis FO, Eholie SP, Maiga M, Amani-Bosse C, et al. Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health. 2010;15(Suppl 1):34-42.
77. Unge C, Sodergard B, Ekstrom AM, Carter J, Waweru M, Ilako F, et al. Challenges for scaling up ART in a resource-limited setting: a retrospective study in Kibera, Kenya. J Acquir Immune Defic Syndr. 2009;50:397-402.
78. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ. 2007;85:550-4.
79. Brinkhof M, Spycher B, Yiannoutsos CT,Weigel R,Wood R, Messou E, et al. Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS One. 2010;5:e14149.
80. Tweya H, Gareta D, Chagwera F, Ben-Smith A, Mwenyemasi J, Chiputula F, et al. Early active follow-up of patients on antiretroviral therapy (ART) who are lost to follow-up: the 'Back-to-Care' project in Lilongwe, Malawi. Trop Med Int Health. 2010;15(Suppl 1):82-9.
81. Harries AD, Zachariah R, Lawn SD, Rosen S. Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health. 2010;15(Suppl 1):70-5.
82. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health. 2010;15(Suppl 1):48-54.
83. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-24.
84. Beauliere A, Toure S, Alexandre PK, Kone K, Pouhe A, Kouadio B, et al. The financial burden of morbidity in HIV-infected adults on antiretroviral therapy in Cote d'Ivoire. PLoS One. 2010;5:e11213.
85. Boyer S, Marcellin F, Ongolo-Zogo P, Abega SC, Nantchouang R, Spire B, et al. Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ. 2009;87:279-87.
86. Dodani S, LaPorte RE. Brain drain from developing countries: how can brain drain be converted into wisdom gain? J R Soc Med. 2005;98:487-91.
87. Ridde V. Per diems undermine health interventions, systems and research in Africa: burying our heads in the sand. Trop Med Int Health. 2010 Jul 28. doi: 10.1111/j.1365-3156.2010.02607.
88. Eholie SP, Ouiminga M, Ehui E, Nzunetu G, Ouattara SI, Konan AV, et al. Avascular osteonecrosis of the femoral head in three West African HIV-infected adults with heterozygous sickle cell disease. Antivir Ther. 2009;14:1011-4.
89. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg. 2007;101:793-8.
90. Zannou DM, Denoeud L, Lacombe K, Amoussou-Guenou D, Bashi J, Akakpo J, et al. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther. 2009;14:371-80.
91. Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, et al. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr. 2009;51:224-30.
92. Negin J, Cumming RG. HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bull World Health Organ. 2010;88:847-53.
93. Mills EJ, Rammohan A, Awofeso N. Ageing faster with AIDS in Africa. Lancet. 2011;377:1131-3.
94. Twagirumukiza M, Nkeramihigo E, Seminega B, Gasakure E, Boccara F, Barbaro G. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res. 2007;5:129-37.
95. Pape J. Global health. Haiti's quake shifts clinic's focus from AIDS to aid. Interview by Jon Cohen. Science. 2010;327:509.
96. Anglaret X, Barre-Sinoussi F, Becquet R, Danel C, Fleutelot E. L'attention aux malades du Sida, baromè tre de l'humanité [AIDS Care as a Barometer of Humanity: the Crisis in Côte d'Ivoire]. Le Monde. 2011; accessed 2011 April 5. Available from: http://www.lemonde.fr/idees/ article/2011/04/05/l-attention-aux-malades-du-sida-barometrede-l-humanite- 1502634-3232.html.
97. Atun R, Bataringaya J. Building a durable response to HIV/AIDS: implications for health systems. J Acquir Immune Defic Syndr. 2011;57:S91-5.